Autor
Esta publicación es el resultado del simposio internacional que la Fundación Dr. Antonio Esteve organizó del 4 al 7 de octubre de 2000 en Lloret de Mar (Girona) sobre identificación de dosis. El libro recoge las ponencias de los científicos que participaron en este simposio y está editado por Alasdair Breckenridge, del Departamento de Farmacología y Terapéutica de laUniversidad de Liverpool. El objetivo de este encuentro y de esta publicación posterior no es otro que el de avanzar en el que probablemente sea uno de los aspectos más complicados de la terapéutica: cómo escoger la dosis más apropiada para cada paciente.
| Capítulos | ||
| Introduction | A. Breckenridge | [wpdm id=262 type=”btn”] |
| List of participants | [wpdm id=263 type=”btn”] | |
| 1. The use of preclinical pharmacokinetic and pharmacodynamic data to predict clinical doses: current and future perspectives | P. Morgan | [wpdm id=242 type=”btn”] |
| 2. Optimal dose identification: predicting a safe dose in man from animal studies | B.K. Park / N.R. Kitteringham / J.L. Maggs / D. Boocock / I. White / R. Elsby / M. Pirmohamed | [wpdm id=243 type=”btn”] |
| 3. Clinical pharmacology of morphine and morphine-6-glucuronide A PK/PD modeling approach | Jörn Lötsch | [wpdm id=244 type=”btn”] |
| 4. The use of cognitive tests to facilitate drug and dose selection in Phase I and to optimise dosing in Phase IV | K.A. Wesnes | [wpdm id=245 type=”btn”] |
| 5. Dose optimization in drug development: role of phase IV trials | P.H. Joubert | [wpdm id=246 type=”btn”] |
| 6. PK/PD approach to dose selection | L.B. Sheiner | [wpdm id=247 type=”btn”] |
| 7. Mechanism-based modelling of CNS drug effect: from receptor pharmacology to clinical trial | M. Danhof | [wpdm id=248 type=”btn”] |
| 8. Pharmacokinetic-pharmacodynamic modeling in anesthesia | P.L. Gambús / H.F. Trocóniz | [wpdm id=249 type=”btn”] |
| 9. Dose optimisation in pain control | H. McQuay | [wpdm id=250 type=”btn”] |
| 10. The dose-concentration-effect relationships—the basis for TDM. A critical appraisal | L.F. Gram | [wpdm id=251 type=”btn”] |
| 11. Medication non-compliance When hard science meets soft science | G. Levy | [wpdm id=252 type=”btn”] |
| 12. Concentration controlled therapy | N.H.G. Holford | [wpdm id=253 type=”btn”] |
| 13. Therapeutic drag monitoring of anti-HIV drags | D.J. Back / S.H. Khoo / S.E. Gibbons / H. Reynolds / J.F. Tjia / C. Merry | [wpdm id=254 type=”btn”] |
| 14. The role of molecular biology in pharmacodynamic | J. Oliver / D.J. Webb | [wpdm id=255 type=”btn”] |
| 15. Genetic and environmental causes for interindividual variability in drug pharmacokinetics | M. Ingelman-Sundberg | [wpdm id=256 type=”btn”] |
| 16. Genetic determinants of dose optimisation: molecular biology in the prevention of drug toxicity | M. Pirmohamed / B. Kevin Park | [wpdm id=257 type=”btn”] |
| 17. Pharmacodynamics of cancer chemotherapy: childhood ALL as a model | W.E. Evans | [wpdm id=258 type=”btn”] |
| 18. Dose optimisation in antidepressant drag development | B. Deakin | [wpdm id=259 type=”btn”] |
| 19. Effect of liver disease on dose optimization | T.F. Blaschke | [wpdm id=260 type=”btn”] |
| 20. Dose optimisation—the effect of age | S.H.D. Jackson | [wpdm id=261 type=”btn”] |
| Final remarks | A. Breckenridge | [wpdm id=264 type=”btn”] |
- 2. Optimal dose identification: predicting a safe dose in man from animal studies
- B.K. Park / N.R. Kitteringham / J.L. Maggs / D. Boocock / I. White / R. Elsby / M. Pirmohamed
- Descargar
- 10. The dose-concentration-effect relationships—the basis for TDM. A critical appraisal
- L.F. Gram
- Descargar
- 18. Dose optimisation in antidepressant drag development
- B. Deakin
- Descargar
- 3. Clinical pharmacology of morphine and morphine-6-glucuronide A PK/PD modeling approach
- Jörn Lötsch
- Descargar
- 11. Medication non-compliance When hard science meets soft science
- G. Levy
- Descargar
- 19. Effect of liver disease on dose optimization
- T.F. Blaschke
- Descargar
- 4. The use of cognitive tests to facilitate drug and dose selection in Phase I and to optimise dosing in Phase IV
- K.A. Wesnes
- Descargar
- 12. Concentration controlled therapy
- N.H.G. Holford
- Descargar
- 20. Dose optimisation—the effect of age
- S.H.D. Jackson
- Descargar
- 5. Dose optimization in drug development: role of phase IV trials
- P.H. Joubert
- Descargar
- 13. Therapeutic drag monitoring of anti-HIV drags
- D.J. Back / S.H. Khoo / S.E. Gibbons / H. Reynolds / J.F. Tjia / C. Merry
- Descargar
- Final remarks
- A. Breckenridge
- Descargar
- 6. PK/PD approach to dose selection
- L.B. Sheiner
- Descargar
- 14. The role of molecular biology in pharmacodynamic
- J. Oliver / D.J. Webb
- Descargar
- Optimal dose identification Introduction
- A. Breckenridge
- Descargar
- 7. Mechanism-based modelling of CNS drug effect: from receptor pharmacology to clinical trial
- M. Danhof
- Descargar
- 15. Genetic and environmental causes for interindividual variability in drug pharmacokinetics
- M. Ingelman-Sundberg
- Descargar
- Optimal dose identification List of participants
- Descargar
- 8. Pharmacokinetic-pharmacodynamic modeling in anesthesia
- P.L. Gambús / H.F. Trocóniz
- Descargar
- 16. Genetic determinants of dose optimisation: molecular biology in the prevention of drug toxicity
- M. Pirmohamed / B. Kevin Park
- Descargar
- 1. The use of preclinical pharmacokinetic and pharmacodynamic data to predict clinical doses: current and future perspectives
- P. Morgan
- Descargar
- 9. Dose optimisation in pain control
- H. McQuay
- Descargar
- 17. Pharmacodynamics of cancer chemotherapy: childhood ALL as a model
- W.E. Evans
- Descargar
